FORT WORTH, Texas & MELBOURNE, Australia–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced the appointments of W…
Author: Business Wire
Veranex Unveils MedTech’s First Innovation CRO (iCRO)—Redefining R&D in a Capital‑Tight Market
RALEIGH, N.C.–(BUSINESS WIRE)– #CRO–Veranex, a global provider of product development and contract research services, today introduced the industry’s first Innovation CRO (iCRO)—an integrated development and research platform engineered to move medi…
Sightview Expands Leadership Bench, Appointing Vice Presidents of Client Operations and Product Management
DURHAM, N.C.–(BUSINESS WIRE)– #EHR–Sightview, the only EHR and practice management partner focused solely on eyecare, has appointed Melissa Wright and Casi Nestleroad as VPs.
EyeDura's Sustained-Release Eye Drop Technology Wins Double Industry Honors
NEW YORK–(BUSINESS WIRE)–EyeDura Therapeutics Inc. (www.eyedura.com), a developer of preservative-free sustained release ophthalmic therapies, announced that it received top recognition at two major industry forums among a field of innovative ophthal…
Golden Age Health e Innostellar Biotherapeutics siglano un accordo di collaborazione esclusiva decennale per accelerare lo sviluppo della terapia genica LX-101 contro le distrofie retiniche ereditarie causate da mutazione del gene RPE65 in Cina
SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) e Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) oggi hanno annunciato la sigla di un accordo esclusivo decennale riguardante servizi di promozione che concede a GAH i diritti esclus…
Golden Age Health e Innostellar Biotherapeutics assinam colaboração exclusiva de 10 anos para acelerar a terapia gênica LX-101 voltada a distrofias hereditárias de retina causadas por mutação no gene RPE 65 na China continental
XANGAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) e a Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) anunciaram hoje um Contrato de Serviços Promocionais exclusivo por dez anos que concede à GAH direitos exclusivos para comercializar …
Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China
SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) and Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) today announced an exclusive ten-year Promotion Services Agreement that grants GAH sole rights to commercialise and promote Innoste…
Lock In Instant Definition and Volume with COVERGIRL’s NEW Mascara
NEW YORK–(BUSINESS WIRE)–Get ready to lock in lashes that feel stronger and protected with COVERGIRL’s latest addition to the Lash Blast portfolio. Say hello to NEW Lash Blast Bond Mascara, formulated to deliver instant definition and up to 5x visibl…
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release secon…
Resumen: ViaLase anuncia cambios estratégicos en la dirección para impulsar el crecimiento comercial
ALISO VIEJO, California–(BUSINESS WIRE)–ViaLase, Inc, empresa dedicada a la tecnología médica pionera en tratamientos no invasivos con láser de femtosegundo para el glaucoma, acaba de anunciar cambios significativos en su equipo directivo mientras la…
Samenvatting: ViaLase kondigt strategische leiderschapswisselingen aan ter ondersteuning van commerciële groei
ALISO VIEJO, Calif.–(BUSINESS WIRE)–ViaLase, Inc., een medisch technologiebedrijf dat pioniert op het gebied van niet-invasieve femtosecondelaserbehandelingen voor glaucoom, heeft vandaag belangrijke wijzigingen in het managementteam aangekondigd, te…
Riassunto: ViaLase annuncia transizioni nella leadership strategica, a supporto della crescita commerciale
ALISO VIEJO, California–(BUSINESS WIRE)–ViaLase, Inc., azienda medico-tecnologica che propone innovativi trattamenti laser a femtosecondi non invasivi contro il glaucoma, oggi ha annunciato importanti cambiamenti nel suo team di alti dirigenti, mentr…
ViaLase annonce des changements stratégiques au sein de sa direction pour soutenir sa croissance commerciale
ALISO VIEJO, Californie–(BUSINESS WIRE)–ViaLase, Inc., entreprise de technologies médicales pionnière dans le traitement non invasif du glaucome par laser femtoseconde, a annoncé aujourd’hui des changements importants au sein de son équipe de directi…
ViaLase kündigt strategische Führungsübergänge zur Unterstützung des kommerziellen Wachstums an
ALISO VIEJO, Kalifornien–(BUSINESS WIRE)–ViaLase, Inc., ein Unternehmen der Medizintechnik, das nicht-invasive Femtosekunden-Laserbehandlungen für Glaukom entwickelt, gab heute wichtige Änderungen in seinem Führungsteam bekannt, da das Unternehmen si…
Durchbruch in der Ophthalmologie: Heng Qin® (Perfluorhexyloctan-Augentropfen) von Hengrui als erstes Arzneimittel zur Behandlung des MGD-assoziierten trockenen Auges zugelassen
JIANGSU, China, HEIDELBERG, Deutschland, und CAMBRIDGE, Massachusetts, USA–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. („Hengrui Pharma“), ein globales Pharmaunternehmen mit Fokus auf wissenschaftliche und technologische Innovationen, u…
Une avancée majeure en ophtalmologie ! Heng Qin® (gouttes ophtalmiques à base de perfluorohexyloctane) de Hengrui est approuvé en tant que premier traitement de la sécheresse oculaire associée au trouble des glandes de Meibomius
JIANGSU, Chine et HEIDELBERG, Allemagne et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. (« Hengrui Pharma »), une société pharmaceutique mondiale axée sur l’innovation scientifique et technologique, et Novaliq Gm…
眼科领域迎来重大突破！Hengrui的Heng Qin®（全氟己基辛烷滴眼液）获批成为首个治疗睑板腺功能障碍(MGD)相关干眼症的药物
中国江苏、德国海德堡和马萨诸塞州剑桥–(BUSINESS WIRE)–(美国商业资讯)– 专注于科技创新的全球性制药企业Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”)与专注于研发基于独特EyeSol®无水技术的同类首创及最佳眼科疗法的生物制药公司Novaliq GmbH (“Novaliq”)今日宣布，中国国家药品监督管理局(NMPA)已批准Heng Qin®（全氟己基辛烷滴眼液）用于治疗与睑板腺功能障碍(MGD)相关的…
Samenvatting: Doorbraak in de oogheelkunde! Heng Qin® (perfluorohexyloctaan oogdruppels) van Hengrui goedgekeurd als eerste behandeling voor droge ogen geassocieerd met MGD
JIANGSU, China & HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. (‘Hengrui Pharma’), een wereldwijd farmaceutisch bedrijf gericht op wetenschappelijke en technologische innovatie, en Novaliq GmbH (‘Nov…
Riassunto: Novità nell'oftalmologia! Heng Qin®, il collirio al perfluorohexyloctane realizzato da Hengrui è stato approvato come primo trattamento per la sindrome dell'occhio secco associata alla MGD
JIANGSU, Cina, HEIDELBERG, Germania e CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), azienda farmaceutica globale incentrata sull’innovazione scientifica e tecnologica, e Novaliq GmbH (“Novaliq”), un’az…
Resumen: Gran avance en oftalmología: Heng Qin® de Hengrui (colirio de perfluorohexiloctano) aprobado como primer tratamiento para la sequedad ocular asociada a la Disfunción de las glándulas de Meibomio
JIANGSU, China y HEIDELBERG, Alemania y CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co. Ltd. («Hengrui Pharma»), una compañía farmacéutica internacional centrada en la innovación científica y tecnológica, y Novaliq GmbH (…